



FOR IMMEDIATE RELEASE

## Significant Shareholder Notice

**Sydney, Australia 24<sup>th</sup> July 2012** - NuSep (ASX: NSP) wishes to advise the market that the attached notice has been received by the Company.

**\*\*ENDS\*\***

### For more information please contact:

Swapna Keskar  
Company Secretary  
+61 2 8415 7300  
[swapna.keskar@nusep.com](mailto:swapna.keskar@nusep.com)





### About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from **Fraction to Function**. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

### NuSep Products:

-  **Gels** – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.
-  **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.
-  **Proteomics Software** – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
-  **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website [www.NuSep.com](http://www.NuSep.com)

### About PRIME Biologics Pte Ltd

PRIME Biologics is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. PRIME Biologics is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). PRIME Biologics process is based on the **Preparative Isolation** by

<b>NuSep Holdings Ltd</b>	<b>Postal Address</b>	<b>Contact Details</b>	<b>Email</b> <a href="mailto:info@nusep.com">info@nusep.com</a>
324 Burns Bay Rd	P.O. Box 823	<b>Telephone</b> +61 2 8415 7300	<b>Web</b> <a href="http://www.nusep.com">www.nusep.com</a>
Lane Cove NSW 2066	Lane Cove NSW 1595	<b>Facsimile</b> +61 2 8415 7399	<b>ABN</b> 33 120 047 556

**Membrane Electrophoresis (PrIME)** technology developed by NuSep. PrIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause 'Mad Cow Disease'. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the *Currently Unprocessable Plasma* which represents approximately 50% of all the plasma collected in many countries.

**Form 604**Corporations Act 2001  
Section 671B**Notice of change of interests of substantial holder**

To Company Name/Scheme

NUSEP HOLDINGS LTD

ACN/ARSN

33 120 047 556

**1. Details of substantial holder(1)**

Name

ANDREW ERNEST GOODALL

ACN/ARSN (if applicable)

There was a change in the interests of the substantial holder on

20/7/12

The previous notice was given to the company on

25/6/12

The previous notice was dated

25/6/12

**2. Previous and present voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
ORDINARY SHARES	19,000,000	17.60 %	22,230,000	19.99 %

**3. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
20/7/12	A. E. GOODALL	Shares	\$ 226,100.00	3,230,000	3,230,000
		resulting from conversion of part of a loan		ORDINARY SHARES	

**4. Present relevant interests**

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
AE GOODALL	AE GOODALL	AE GOODALL	DIRECT	22,230,000	19.99%

**5. Changes in association**

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association

**6. Addresses**

The addresses of persons named in this form are as follows:

Name	Address
A.E. GOODALL	554 KYOGLE ROAD MURUMBUMBAH NSW 2484

**Signature**

print name

ANDREW GOODALL

capacity

sign here



date 23 / 07 / 2012

**DIRECTIONS**

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (6) Include details of:
  - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
- (9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.